Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

Department of Medicine, University of California, Los Angeles.

Triggered activity due to early afterdepolarizations in the context of prolonged repolarization is believed to cause torsade de pointes. The nature of such triggered activity is not clearly defined. Spontaneous action potentials developing from depolarized membrane potentials were studied in canine Purkinje fibers with use of a standard microelectrode technique. Action potentials due to abnormal automaticity and additional depolarizations developing over the repolarization phase were induced by 5 mM barium superfusion. These action potentials were abolished by 1.0 x 10(-5) M verapamil and by calcium-free solution, whereas action potential amplitude (Vmax) and spontaneous firing frequency were markedly enhanced by 2.0 x 10(-6) M isoproterenol. High calcium solution shortened the action potential duration and precluded additional depolarizations. Quinidine, 1.0 x 10(-5) M, reduced action potential amplitude (6.9 +/- 1.8%: p less than 0.01), Vmax (15.7 +/- 4.0%; p less than 0.05) and spontaneous firing frequency (18.5 +/- 2.1%; p less than 0.01), but it increased action potential duration measured at -40 mV (19.1 +/- 5.9%; p less than 0.01), which produced additional depolarizations. Amiodarone, 5.0 x 10(-5) M, reduced action potential amplitude (23.4 +/- 3.6%; p less than 0.01), Vmax (44.6 +/- 3.9%; p less than 0.01) and spontaneous firing frequency (41.9 +/- 5.1%; p less than 0.01). Amiodarone obviated the development of additional depolarizations without effect on action potential duration.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T. Fetsch, P. Bauer, R. Engberding, H. P. Koch, J. Lukl, T. Meinertz, M. Oeff, L. Seipel, H. J. Trappe, N. Treese, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial Eur. Heart J., August 2, 2004; 25(16): 1385 - 1394. [Abstract] [Full Text] [PDF]

				B. N. Singh and N. Wadhani Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S85 - S97. [Abstract] [PDF]

				B. N. Singh and J. S. M. Sarma Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 69 - 87. [PDF]

				K. Glatter, Y. Yang, K. Chatterjee, G. Modin, J. Cheng, S. Kayser, and M. M. Scheinman Chemical Cardioversion of Atrial Fibrillation or Flutter With Ibutilide in Patients Receiving Amiodarone Therapy Circulation, January 16, 2001; 103(2): 253 - 257. [Abstract] [Full Text] [PDF]

				L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt Experimental models of torsade de pointes Cardiovasc Res, July 1, 1998; 39(1): 178 - 193. [Abstract] [Full Text] [PDF]

				C. Fiset, B. Drolet, B. A. Hamelin, and J. Turgeon Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 148 - 156. [Abstract] [Full Text]

				I. Kodama, K. Kamiya, and J. Toyama Cellular electropharmacology of amiodarone Cardiovasc Res, July 1, 1997; 35(1): 13 - 29. [Full Text] [PDF]

				C. Takanaka, K. O. Ogunyankin, J.S.M. Sarma, and B. N. Singh Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of Magnesium and Lidocaine in Torsade de Pointes Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(2): 125 - 134. [Abstract] [PDF]

				D. W. Krichbaum and D. A. Trivedi Thrombolytic Therapy in Acute Myocardial Infarction Journal of Pharmacy Practice, January 1, 1990; 3(5): 332 - 348. [PDF]